SEC Form 4 · accession 0001237899-18-000026
REGENERON PHARMACEUTICALS, INC. · REGN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Christopher R. Fenimore
Officer — VP Controller
Period of report
Dec 19, 2018
Accepted (ET)
Dec 20, 2018 · 5:36 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000872589
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Dec 19, 2018 | M | 3,450 | $52.03 | A | 9,871 | D | |
| Common Stock | Dec 19, 2018 | F | 1,602 | $364.42 | D | 8,269 | D | |
| Common Stock | Dec 20, 2018 | M | 675 | $21.25 | A | 8,944 | D | |
| Common Stock | Dec 20, 2018 | S | 100 | $355.14 | D | 8,844 | D | |
| Common StockF2 | Dec 20, 2018 | S | 348 | $356.27 | D | 8,496 | D | |
| Common StockF3 | Dec 20, 2018 | S | 200 | $357.50 | D | 8,296 | D | |
| Common StockF4 | Dec 20, 2018 | S | 200 | $358.27 | D | 8,096 | D | |
| Common StockF5 | Dec 20, 2018 | S | 200 | $359.38 | D | 7,896 | D | |
| Common StockF6 | Dec 20, 2018 | S | 500 | $360.40 | D | 7,396 | D | |
| Common Stock | Dec 20, 2018 | S | 100 | $361.65 | D | 7,296 | D | |
| Common StockF7 | Dec 20, 2018 | S | 200 | $362.45 | D | 7,096 | D | |
| Common Stock | holding | — | — | — | 1,349 | I | By 401(k) Plan | |
| Common StockF8 | holding | — | — | — | 1,397 | I | By Trust | |
| Common Stock | holding | — | — | — | 1,424 | I | by 2017 GRAT | |
| Common Stock | holding | — | — | — | 2,950 | I | by 2018 GRAT |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Incentive Stock Option (right to buy)F9 | $21.25 | Dec 20, 2018 | M | 675 | D | — | Dec 18, 2019 | Common Stock | 675 | 500 | D |
| Non-Qualified Stock Option (right to buy)F9 | $52.03 | Dec 19, 2018 | M | 3,450 | D | — | Dec 16, 2021 | Common Stock | 3,450 | 10,326 | D |
Explanation of responses
- F1Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).
- F2Represents volume-weighted average price of sales of 348 shares of Company stock on December 20, 2018 at prices ranging from $356.22 to $356.34. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 20, 2018 at each separate price.
- F3Represents volume-weighted average price of sales of 200 shares of Company stock on December 20, 2018 at prices ranging from $357.15 to $357.85. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 20, 2018 at each separate price.
- F4Represents volume-weighted average price of sales of 200 shares of Company stock on December 20, 2018 at prices ranging from $358.18 to $358.35. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 20, 2018 at each separate price.
- F5Represents volume-weighted average price of sales of 200 shares of Company stock on December 20, 2018 at prices ranging from $359.18 to $359.57. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 2018 at each separate price.
- F6Represents volume-weighted average price of sales of 500 shares of Company stock on December 20, 2018 at prices ranging from $360.18 to $360.72. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 20, 2018 at each separate price.
- F7Represents volume-weighted average price of sales of 200 shares of Company stock on December 20, 2018 at prices ranging from $362.02 to $362.87. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 20, 2018 at each separate price.
- F8These shares are held in a trust for the benefit of the reporting person's spouse. The reporting person and the reporting person's spouse are trustees of the trust.
- F9The stock option award (combined incentive stock option and non-qualified stock option) vests in four equal annual installments, commencing one year after the date of grant.